Animal testing is declining, and the trend is accelerating, but a complete end is still decades away. Several governments have set formal phase-out targets, new technologies are outperforming animals in key areas of drug safety screening, and public support for the practice has dropped to 44%. The realistic picture is not a single moment when animal testing “stops” but a gradual replacement, organ system by organ system, regulation by regulation, until only a small fraction of current testing remains.
Where Things Stand Right Now
Public opinion has shifted substantially against animal testing. A national survey published in the American Journal of Veterinary Research found that only 44% of respondents considered it acceptable to use animals in laboratory research. Cosmetic testing on animals fared even worse, with just 31% approval, putting it on par with trophy hunting in public acceptability. When people were told about ethical oversight and mutual benefits for humans and animals, acceptance rose to 55%, but strong opposition still sat at 35%. The cultural momentum is clearly moving in one direction.
That shift is now showing up in law and policy. The FDA Modernization Act 2.0, signed in late 2022, removed the longstanding federal requirement that new drugs be tested on animals before entering human trials. This doesn’t ban animal testing. It simply means drug developers can now choose validated alternatives instead. The U.S. Environmental Protection Agency has gone further, setting a goal to eliminate all mammalian animal testing for chemical safety evaluations by 2035. The European Union banned cosmetic testing on animals back in 2013, and dozens of other countries have followed with similar bans on cosmetics.
Technologies That Are Replacing Animals
The strongest argument that animal testing will eventually end isn’t moral. It’s scientific. In several important areas, newer methods already work better than animals do.
Organ-on-a-chip technology is the clearest example. These are small devices containing living human cells arranged to mimic the structure and function of a real organ. In one study testing liver toxicity, a liver chip correctly identified toxic drugs with 87% sensitivity. The animal models used on the same set of drugs scored 0%. That’s not a marginal improvement. The chip caught seven out of eight dangerous drugs that animals completely missed. Because these chips use human cells, they avoid one of the fundamental problems with animal testing: the biological differences between species that cause drugs to behave differently in mice or rats than they do in people.
Artificial intelligence is reshaping the earliest stages of drug development even more broadly. Computational models can now predict how a molecule will interact with its target, how the body will absorb and break it down, and whether it’s likely to be toxic, all before any living thing is exposed to it. Nearly 40% of published AI drug discovery research focuses on the preclinical stage, where AI handles tasks like virtual screening, molecule design, and toxicity prediction. These tools don’t just spare animals. They compress timelines from years to weeks and screen millions of compounds that no lab could physically test.
Why Some Animal Testing Persists
The human body is not a collection of independent organs. It’s a network where hormones, immune cells, gut bacteria, and circulating molecules all talk to each other constantly. That interconnectedness is the core reason animal testing hasn’t ended already. A liver chip can tell you whether a drug damages liver cells. It cannot tell you whether that drug disrupts hormone signaling between the brain and the thyroid, alters the gut microbiome in a way that weakens immune defense, or causes a developing fetus to form abnormally.
Infectious diseases are a clear example. When a pathogen enters the body, it spreads through the bloodstream, triggers immune responses across multiple organs, and interacts with the unique microbial ecosystem each individual carries. No chip, no computer model, and no cell culture can fully reproduce that cascade. The same is true for neurological conditions, autoimmune diseases, and anything involving the complex feedback loops of the endocrine system. Scientists are, frankly, very far from being able to predict how a complex organism functions from studying its parts in isolation.
This doesn’t mean whole-organism testing must involve animals forever. But it does mean that replacing animal models for systemic, multi-organ questions requires a level of technology that doesn’t yet exist. The path forward likely involves linking multiple organ chips together into “body-on-a-chip” systems, combining those with AI predictions, and validating the results against human clinical data over many years.
A Realistic Timeline
Animal testing will not end on a single date. It’s more useful to think of it in tiers. Cosmetic testing on animals is already illegal in over 40 countries and will likely be banned in most major markets within the next decade. Chemical safety testing, the EPA’s domain, has a formal 2035 target, though whether that deadline holds depends on how quickly alternative methods pass regulatory validation. Drug development is the hardest category, and the timeline there is the longest.
For pharmaceutical testing, the realistic trajectory looks something like this: over the next 10 to 15 years, AI and organ chips will replace animals in early-stage screening for toxicity and drug metabolism. This is already happening. The middle stage, where researchers need to understand how a drug behaves in a full biological system, will take longer. Replacements for whole-animal studies in areas like reproductive toxicity, cancer metastasis, and immune response could take 20 to 30 years or more to develop and validate.
Regulatory inertia adds another layer of delay. Even when a new method is scientifically superior, getting it formally accepted by agencies like the FDA or the European Medicines Agency involves years of comparison studies, guideline revisions, and international harmonization. The FDA Modernization Act 2.0 was a landmark because it removed a legal barrier, but the practical shift in how companies design their testing programs will unfold gradually.
What “Stopping” Actually Looks Like
The number of animals used in research has already dropped significantly from its peak in the 1970s and 1980s, driven by the “3Rs” framework: replace animals where possible, reduce the number used, and refine procedures to minimize suffering. What’s happening now is an acceleration of the “replace” part of that framework, powered by technology that simply didn’t exist a decade ago.
The honest answer to whether animal testing will ever stop completely is: probably, but not in any of our immediate planning horizons. Cosmetic and chemical testing on animals is nearing its end. Routine drug toxicity screening is shifting to chips and computers right now. But the last 10 to 20% of animal research, the studies involving complex whole-body systems and diseases we don’t yet fully understand, will be the hardest to replace and the last to go. The question is less “if” than “when,” and “when” is measured in decades, not years.